Sunday, August 02, 2020 3:41:31 PM
Below was her response :
“ABMC would like nothing more than our stock price to appreciate but on fundamentals only. We will not make statements that are not based in fact. We reported on June 26th that we have recorded$1M in sales; that is very positive considering our total revenues in all of 2019.
Surges negatively impact the demand for antibodies tests as during surges focus is put back on PCR based tests. Please also remember that these are medical devices. People do not just call and place an order immediately without doing their own due diligence and often validation testing. The sales cycles can therefore be longer than (for instance) a tongue depressor. Regardless of what is being “rumored” to be true, investor should only rely on information that comes directly from the company.”
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM